吡咯替尼靶向治疗对不同CA125表达水平的乳腺癌患者的治疗效果

Effect of pyrrolidine targeted therapy on breast cancer patients with different levels of CA125 expression

目的:探讨吡咯替尼靶向治疗对不同癌抗原125(CA125)表达水平的乳腺癌患者的治疗效果。方法:选取106例乳腺癌患者为研究对象,将CA125>16 U/mL的52例患者作为对照组;CA125≤31.47 U/mL的54例患者作为研究组,两组患者均采用吡咯替尼靶向治疗4个月。观察两组治疗前及治疗4个月后临床疗效,检测比较两组治疗前后免疫球蛋白、肿瘤血管生长因子、肿瘤标志物、炎症反应水平。结果:与对照组相比,研究组总有效率高于对照组(P<0.05)。治疗后,两组免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、肿瘤特异性生长因子(TSGF)、血管内皮生长因子(VEGF)、癌抗原153(CA153)、组织多肽特异性抗原(TPS)、癌胚抗原(CEA)、肿瘤坏死因子α(TNF-ɑ)、白细胞介素6(IL-6)、C反应蛋白(CRP)水平均降低,且研究组低于对照组(P<0.05)。与对照组相比,研究组皮肤破溃缓解、疼痛缓解、乳腺肿块缓解、淋巴结肿大缓解时间均较短(P<0.05)。结论:乳腺癌患者采用吡咯替尼靶向治疗后,可抑制肿瘤标志物表达,改善患者免疫功能,且相对于CA125高表达水平的患者,CA125低表达患者治疗效果较好,可改善患者临床症状,促使患者的恢复。

Objective:To study the therapeutic effect of pyrrolidine targeted therapy on breast cancer patients with different levels of cancer antigen 125(CA125)expression.Methods:106 patients with breast cancer were selected as the study objects,52 patients with CA125>16 U/mL as the control group,and 54 patients with CA125≤31.47 U/mL as the study group.Both groups of patients were treated with pyrrolidine targeted therapy for 4 months.The clinical efficacy of two groups before treatment and 4 months after treatment were observed,and the levels of immunoglobulin,tumor vascular growth factor,tumor markers,and inflammatory response between the two groups before and after treatment were compared.Results:Compared with the control group,the total effective rate of the study group was higher(P<0.05).Compared with before treatment,the levels of immunoglobulin M(IgM),immunoglobulin G(IgG),immunoglobulin A(IgA),tumor specific growth factor(TSGF),vascular endothelial growth factor(VEGF),cancer antigen 153(CA153),tissue peptide specific antigen(TPS),carcinoembryonic antigen(CEA),and tumor necrosis factor-α(TNF-ɑ),interleukin-6(IL-6)and C-reactive protein(CRP)of the two groups after treatment decreased,and the study group was lower than the control group(P<0.05).Compared with the control group,the study group had shorter relief times for skin ulcers,pain,breast lumps,and lymph node enlargement(P<0.05).Conclusion:After targeted treatment of breast cancer patients with pyrrolidine,it can inhibit the expression of tumor markers and improve the immune function of patients.Compared with patients with high expression of CA125,patients with low expression of CA125 have a better therapeutic effect,which can improve the clinical symptoms of patients and promote the recovery of patients.